Clinical Trial Detail

NCT ID NCT03012321
Title Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements Yes
Sponsors Northwestern University
Indications

prostate adenocarcinoma

Therapies

Abiraterone + Olaparib + Prednisone

Abiraterone + Prednisone

Olaparib

Age Groups: adult senior

Additional content available in CKB BOOST